Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Nanfang Hospital, Southern Medical University
Eli Lilly and Company
National Cancer Institute (NCI)
The New York Proton Center
Iambic Therapeutics, Inc
National Cancer Institute (NCI)
Stemline Therapeutics, Inc.
Wake Forest University Health Sciences
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
NRG Oncology
NRG Oncology
Mayo Clinic
Mayo Clinic
Institut Cancerologie de l'Ouest
Weill Medical College of Cornell University
Avera McKennan Hospital & University Health Center
InSightec
Orano Med LLC
Brigham and Women's Hospital
Centre Oscar Lambret
Stanford University
Filamon LTD
AstraZeneca
MedSIR
MedSIR
Hoffmann-La Roche
Baptist Health South Florida
UMC Utrecht
Thomas Jefferson University
City of Hope Medical Center
Essen Biotech
Essen Biotech
AstraZeneca
Sapience Therapeutics
Barbara Ann Karmanos Cancer Institute
University of Nebraska
Adela, Inc
Eli Lilly and Company
M.D. Anderson Cancer Center
Var2 Pharmaceuticals
Hoosier Cancer Research Network
Stanford University
Mayo Clinic
Sunnybrook Health Sciences Centre
University of Rochester
Mayo Clinic
University of Washington
AstraZeneca